MedTrace Logo

Unique Treatment of Oncology Pain in Advanced Cancer

NCT06533657 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-04-21

No results posted yet for this study

Summary

This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to severe chronic pain and who are taking a stable dose of long-acting opioid therapy for at least 1 week prior to screening.

Conditions

  • Cancer Pain

Interventions

DRUG

Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)

Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.

Sponsors & Collaborators

  • ZYUS Life Sciences Inc.

    lead INDUSTRY

Principal Investigators

  • Julie Stakiw, MD · Saskatoon Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2026-04-15
Completion
2026-04-15

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06533657 on ClinicalTrials.gov